Pivotal head-to-head trial shows benefit of Kyprolis® over Velcade®

The results of the first head-to-head Phase III trial comparing two proteasome inhibitors, have demonstrated the benefits of Kyprolis over Velcade for relapsed and/or refractory myeloma patients. Published online in the Lancet Oncology, the ENDEAVOR trial compared outcomes for 929 patients randomised to receive either Kyprolis and low-dose dexamethasone (Kd) or Velcade and low-dose dexamethasone (Vd),…

Details